Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Zepbound Powers Eli Lilly's Upbeat Q2 Outlook
02:55pm, Wednesday, 09'th Jul 2025
Eli Lilly and Co. LLY is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 bil
US FDA approves gradual dosing for Lilly Alzheimer's drug
06:48am, Wednesday, 09'th Jul 2025
The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous t
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
06:45am, Wednesday, 09'th Jul 2025
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS , July 9, 2025
Don't Miss Out: 3 Blue-Chips Set to Pop This Earnings Season
04:46pm, Tuesday, 08'th Jul 2025
As we enter a new earnings season, there are several reasons for optimism about the economy. However, potential headwinds remain, causing some investors to focus on what could happen rather than what
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
01:41pm, Tuesday, 08'th Jul 2025
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying
3 Underrated Dividend Growth Stocks to Buy and Hold for Years
04:55am, Tuesday, 08'th Jul 2025
When you think of a great dividend stock to own, you're probably thinking of one that yields a high rate of return. But focusing on yield alone can be a mistake.
Demand for obesity drugs shoots up in India as Lilly, Novo jostle for market share
06:48am, Monday, 07'th Jul 2025
Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly and Novo Nordisk are competing for market share, data from research firm Pharmarack showed on Monday.
3 No-Brainer Stocks to Buy in July
06:40am, Monday, 07'th Jul 2025
Don't let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies.
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
03:45am, Monday, 07'th Jul 2025
Though you may think "tech stocks" when someone mentions growth, you actually can find growth stocks throughout a wide variety of industries. Even those like pharmaceuticals, often known for the stead
2 Dividend Growth Stocks to Buy and Hold Forever
07:05am, Sunday, 06'th Jul 2025
For investors focused on the long game, there is little reason to sell -- at least, so long as a company generates solid returns through consistently improving financial results, regularly increases i
Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.
01:01am, Friday, 04'th Jul 2025
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with Lilly and Novo.
Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?
10:30am, Wednesday, 02'nd Jul 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Top 50 High-Quality Dividend Stocks For July 2025
08:56am, Wednesday, 02'nd Jul 2025
I track 50 high-quality dividend growth stocks to identify opportune investments, updating valuation ratings daily to focus on attractive opportunities. In this turbulent year, my investable universe
2 Growth Stocks to Buy Hand Over Fist in July
04:01am, Wednesday, 02'nd Jul 2025
July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least.
Top 15 High-Growth Dividend Stocks For July 2025
09:02pm, Tuesday, 01'st Jul 2025
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, tho
